$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000139047814000043 Filed on August 11, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$1.620M	$2.331M	$3.382M
YoY Change	-25.21%	-31.08%	0.0%
Cost Of Revenue	$247.0K	$347.0K	$0.00
YoY Change	-4.26%
Gross Profit	$1.373M	$1.984M	$2.914M
YoY Change	-5.57%	-31.91%	0.0%
Gross Profit Margin	84.75%	85.11%	86.16%
Selling, General & Admin	$3.542M	$9.600M	$2.710M
YoY Change	-14.22%	254.24%	38.27%
% of Gross Profit	257.98%	483.87%	93.0%
Research & Development	$7.025M	$8.069M	$5.276M
YoY Change	93.37%	52.94%	41.83%
% of Gross Profit	511.65%	406.7%	181.06%
Depreciation & Amortization	-$120.0K	$230.0K	$40.00K
YoY Change	-192.31%	475.0%
% of Gross Profit	-8.74%	11.59%	1.37%
Operating Expenses	$10.57M	$17.67M	$7.986M
YoY Change	36.14%	121.25%	40.52%
Operating Profit	-$10.57M	-$15.78M	-$7.986M
YoY Change	53.3%	97.63%	188.41%
Interest Expense	$6.440M	-$3.670M	-$130.0K
YoY Change	-680.18%	2723.08%	-101.97%
% of Operating Profit
Other Income/Expense, Net	-$6.173M	-$19.94M	-$8.056M
YoY Change	-24.05%	147.53%	-236.31%
Pretax Income	-$3.530M	-$15.95M	-$8.056M
YoY Change	-56.57%	97.99%	-3648.9%
Income Tax	$0.00	$0.00	$1.541M
% Of Pretax Income
Net Earnings	-$6.173M	-$19.94M	$5.389M
YoY Change	-10.91%	-470.03%	-134.41%
Net Earnings / Revenue	-381.05%	-855.47%	159.34%
Basic Earnings Per Share	-$0.05		$0.59
Diluted Earnings Per Share	-$890.1M	-$4.029B	-$0.11
COMMON SHARES
Basic Shares Outstanding	118.2M shares	118.0M shares	83.66M shares
Diluted Shares Outstanding			83.66M shares

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.60M	$39.20M	$26.71M
YoY Change	-54.64%	46.79%	39.09%
Cash & Equivalents	$24.65M	$39.16M	$20.92M
Short-Term Investments			$5.786M
Other Short-Term Assets	$2.000M	$1.900M	$500.0K
YoY Change	233.33%	280.0%	-44.44%
Inventory	$450.0K	$433.0K	$352.0K
Prepaid Expenses
Receivables	$1.435M	$2.152M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$28.52M	$43.68M	$27.55M
YoY Change	-49.77%	58.57%	37.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$589.0K	$623.0K	$467.0K
YoY Change	8.07%	33.4%
Goodwill	$5.898M	$5.898M	$5.898M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.800M	$100.0K	$100.0K
YoY Change	7700.0%	0.0%	0.0%
Total Long-Term Assets	$50.97M	$36.59M	$34.45M
YoY Change	47.88%	6.21%	82.3%
TOTAL ASSETS
Total Short-Term Assets	$28.52M	$43.68M	$27.55M
Total Long-Term Assets	$50.97M	$36.59M	$34.45M
Total Assets	$79.49M	$80.28M	$62.00M
YoY Change	-12.89%	29.47%	58.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.360M	$2.036M	$2.092M
YoY Change	77.78%	-2.68%	23.06%
Accrued Expenses	$15.29M	$11.79M	$8.444M
YoY Change	72.03%	39.61%	462.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.163M	$4.076M	$301.0K
YoY Change	242.63%	1254.15%
Total Short-Term Liabilities	$31.59M	$33.41M	$25.75M
YoY Change	-13.5%	29.75%	176.9%
LONG-TERM LIABILITIES
Long-Term Debt	$5.097M	$6.003M	$9.403M
YoY Change	-40.62%	-36.16%
Other Long-Term Liabilities	$6.900M	$7.500M	$6.500M
YoY Change	6.15%	15.38%	20.37%
Total Long-Term Liabilities	$5.097M	$6.003M	$9.403M
YoY Change	-40.62%	-36.16%	74.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.59M	$33.41M	$25.75M
Total Long-Term Liabilities	$5.097M	$6.003M	$9.403M
Total Liabilities	$48.63M	$51.97M	$46.77M
YoY Change	-14.13%	11.11%	136.22%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$242.2M	$233.5M	$136.7M
YoY Change	44.94%	70.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M	$3.849M	$3.849M
YoY Change	0.0%	0.0%
Treasury Stock Shares	675.0K shares	675.0K shares	675.0K shares
Shareholders Equity	$30.86M	$28.31M	$15.23M
YoY Change
Total Liabilities & Shareholders Equity	$79.49M	$80.28M	$62.00M
YoY Change	-12.89%	29.47%	58.98%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$6.173M	-$19.94M	$5.389M
YoY Change	-10.91%	-470.03%	-134.41%
Depreciation, Depletion And Amortization	-$120.0K	$230.0K	$40.00K
YoY Change	-192.31%	475.0%
Cash From Operating Activities	-$11.12M	-$12.97M	-$7.120M
YoY Change	39.17%	82.16%	5.64%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$310.0K	-$440.0K
YoY Change	-80.0%	-29.55%
Acquisitions			$10.00M
YoY Change
Other Investing Activities	-$3.060M	$0.00	$580.0K
YoY Change	-477.78%	-100.0%	-744.44%
Cash From Investing Activities	-$3.080M	-$310.0K	$130.0K
YoY Change	-527.78%	-338.46%	-244.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-330.0K	20.00K	10.43M
YoY Change	-100.87%	-99.81%	-39.92%
NET CHANGE
Cash From Operating Activities	-11.12M	-12.97M	-7.120M
Cash From Investing Activities	-3.080M	-310.0K	130.0K
Cash From Financing Activities	-330.0K	20.00K	10.43M
Net Change In Cash	-14.53M	-13.26M	3.440M
YoY Change	-147.69%	-485.47%	-67.33%
FREE CASH FLOW
Cash From Operating Activities	-$11.12M	-$12.97M	-$7.120M
Capital Expenditures	-$20.00K	-$310.0K	-$440.0K
Free Cash Flow	-$11.10M	-$12.66M	-$6.680M
YoY Change	40.68%	89.52%	-0.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2660000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2036000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2152000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3683000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11789000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8667000	USD
CY2014Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2343000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	713000	USD
CY2013Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	158000	USD
CY2014Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	280000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	188600000	USD
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	233501000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	158000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	2978000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3136000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	883000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1452000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	519000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	189000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2014Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	98000	USD
CY2013Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19626000	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22377000	shares
CY2013Q4	us-gaap	Assets Assets	87976000	USD
CY2014Q2	us-gaap	Assets Assets	80276000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	53455000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	43684000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000	USD
CY2014Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000	USD
CY2014Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	19000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	26000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47787000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39162000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20919000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32807000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11888000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8625000	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.47
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.50
CY2013Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0.35	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	9460000	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14850000	shares
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	21926000	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110100701	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	118700812	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	118025812	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109425701	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	11000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:inherit;font-size:10pt;"> — Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the company’s cash equivalents were invested in money market mutual funds. The company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
	us-gaap	Cost Of Revenue CostOfRevenue	678000	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	347000	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	7986000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	14597000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	18114000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	32136000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0845
CY2013Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P30M
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1221000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2014Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	108000	USD
CY2013Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	115000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	41000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	461000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1999000	USD
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1683000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7Y
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7534
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0120
	us-gaap	Gain Loss On Sale Of Securities Net GainLossOnSaleOfSecuritiesNet	578000	USD
	us-gaap	Gain Loss On Sale Of Securities Net GainLossOnSaleOfSecuritiesNet	0	USD
CY2013Q4	us-gaap	Goodwill Goodwill	5898000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	5898000	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1541000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1221000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	116000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-624000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1531000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3122000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1494000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	352000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	47000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	339000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-151000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1000	USD
CY2014Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-314000	USD
CY2013Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-186000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-181000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-628000	USD
	us-gaap	Interest Paid InterestPaid	-53000	USD
	us-gaap	Interest Paid InterestPaid	-423000	USD
CY2014Q2	us-gaap	Interest Payable Current InterestPayableCurrent	70000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	70000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	116000	USD
CY2014Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	200000	USD
CY2014Q2	us-gaap	Inventory Net InventoryNet	433000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	386000	USD
CY2014Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	233000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	270000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	82090000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	312000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
CY2014Q2	us-gaap	Liabilities Liabilities	51965000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87976000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80276000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62447000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	33413000	USD
CY2014Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	4076000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2149000	USD
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6003000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7743000	USD
CY2013Q2	us-gaap	Marketable Securities MarketableSecurities	5786000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	578000	USD
CY2014Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2013Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	578000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3108000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10522000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14739000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2344000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9956000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21020000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12454000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18890000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-9597000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-19941000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22477000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	-5000000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20111000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22477000	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8056000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19941000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7986000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27632000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14597000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15783000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-17003000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11979000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-19941000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22477000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	795000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	795000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	312000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	3903000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax		USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-3128000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1533000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-1229000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Other Income OtherIncome	188000	USD
	us-gaap	Other Income OtherIncome	-656000	USD
CY2014Q2	us-gaap	Other Income OtherIncome	-491000	USD
CY2013Q2	us-gaap	Other Income OtherIncome	634000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5155000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-70000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4158000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5514000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2315000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10083000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2013Q4	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10086000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	450000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1737000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1399000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	10000	USD
CY2013Q2	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	0	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div></div>
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9865000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	35000000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5200000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	578000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4070000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	623000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	665000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	17000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	7000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8069000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5276000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10357000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14839000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000	USD
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000	USD
	us-gaap	Sales Discounts Services SalesDiscountsServices	0	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	4504000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2331000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7964
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4240000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16430000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9600000	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2710000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	615000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3136000	USD
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7976
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7766
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7818
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0135
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0125
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0202
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0203
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4841000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13207000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	500000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	835000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.79
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.43
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6308000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10166000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13159000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.73
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.21
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	2755000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.30
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.13
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.57
CY2013Q3	us-gaap	Share Price SharePrice	2.00
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M28D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2012Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	17500000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3328000	shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	37605000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	91000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4070000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	5886000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	28311000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5886000	USD
CY2014Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28311000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> — The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div>
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	83656184	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	117154099	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118083988	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	83331059	shares
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	6439000	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-5521000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-656000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-387000	USD
CY2014Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	490000	USD
CY2013Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-56000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	387000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	656000	USD
	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-6439000	USD
	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	5690000	shares
CY2013Q2	gale	Classof Warrantor Right Average Market Price Used For Exercise Price ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice	P20D
	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	300000	shares
CY2013Q2	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P7Y
CY2014Q2	gale	Contract Research Payable ContractResearchPayable	5108000	USD
CY2013Q2	gale	Debt Instrument Cash Facility Fee DebtInstrumentCashFacilityFee	0.01
CY2013Q2	gale	Debt Instrument Cash Final Payment DebtInstrumentCashFinalPayment	0.055
CY2013Q2	gale	Debt Instrument Term Interest Only DebtInstrumentTermInterestOnly	P12M
CY2014Q2	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-201352000	USD
CY2013Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-178875000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	7936000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y7M13D
CY2014Q2	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	708000	shares
	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	-91000	USD
	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	-44000	USD
CY2013Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6821000	USD
CY2014Q2	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	7477000	USD
CY2013Q4	gale	Contract Research Payable ContractResearchPayable	3109000	USD
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	262000	USD
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	0	USD
	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	-27020000	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity		USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	0	USD
CY2013Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	48965000	USD
CY2014Q2	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	15506000	USD
CY2014Q2	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	15506000	USD
CY2013Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	48965000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	1.93
CY2014Q2	gale	Gale401rights GALE401rights	2315000	USD
CY2013Q4	gale	Gale401rights GALE401rights	0	USD
CY2014Q2	gale	Gross Revenueof Significant Order GrossRevenueofSignificantOrder	1500000	USD
CY2014Q2	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2013Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2013Q2	gale	Interest Income InterestIncome	634000	USD
CY2014Q2	gale	Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents	P90D
CY2014Q2	gale	Mills Pharamaceuticals Milestone1 MillsPharamaceuticalsMilestone1	2000000	shares
CY2014Q2	gale	Interest Income InterestIncome	-491000	USD
	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone	0	USD
	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone	1000000	USD
CY2013Q2	gale	Loss On Warrant Exchange LossOnWarrantExchange	518000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	5521000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	-6439000	USD
CY2014Q2	gale	Loss On Warrant Exchange LossOnWarrantExchange	3353000	USD
CY2014Q2	gale	Mills Pharamaceuticals Milestone2 MillsPharamaceuticalsMilestone2	2000000	shares
CY2014Q2	gale	Mills Pharmaceuticals Maximum Shares Issuablefor Milestones MillsPharmaceuticalsMaximumSharesIssuableforMilestones	3000000	shares
CY2014Q2	gale	Mills Pharmaceuticals Pricepersharefloor MillsPharmaceuticalsPricepersharefloor	4.84
CY2014Q2	gale	Mills Pharmaceuticalspricepershareceiling MillsPharmaceuticalspricepershareceiling	6.84
CY2014Q2	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	-1000	USD
	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	-3000	USD
CY2013Q2	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	0	USD
	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	0	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	630000	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	10585000	USD
CY2014Q2	gale	Net Revenueof Significant Order NetRevenueofSignificantOrder	900000	USD
CY2014Q2	gale	Numberof Commerical Products NumberofCommericalProducts	1	products
CY2013Q2	gale	Numberof Days Averagedfor Exercise Price NumberofDaysAveragedforExercisePrice	P20D
CY2014Q2	gale	Numberof Dosing Strengths NumberofDosingStrengths	6	dosing_strength
CY2013Q3	gale	Numberof Shares Per Unit NumberofSharesPerUnit	1	shares
CY2014Q2	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	1592000	shares
CY2013Q4	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	2618000	USD
CY2014Q2	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	2305000	USD
CY2013Q3	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	37500000	USD
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	1207000	USD
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	27020000	USD
CY2014Q2	gale	Sales And Distributions Rights SalesAndDistributionsRights	14784000	USD
CY2013Q4	gale	Sales And Distributions Rights SalesAndDistributionsRights	14979000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	544000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	0	USD
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	182186	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	118205165	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
	dei	Trading Symbol TradingSymbol	GALE

Files In Submission

Name	View Source	Status
0001390478-14-000043-index-headers.html	Edgar Link	pending
0001390478-14-000043-index.html	Edgar Link	pending
0001390478-14-000043.txt	Edgar Link	pending
0001390478-14-000043-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gale-20140630.xml	Edgar Link	completed
gale-20140630.xsd	Edgar Link	pending
gale-20140630x10q.htm	Edgar Link	pending
gale-20140630xex101.htm	Edgar Link	pending
gale-20140630xex311.htm	Edgar Link	pending
gale-20140630xex312.htm	Edgar Link	pending
gale-20140630xex321.htm	Edgar Link	pending
gale-20140630_cal.xml	Edgar Link	unprocessable
gale-20140630_def.xml	Edgar Link	unprocessable
gale-20140630_lab.xml	Edgar Link	unprocessable
gale-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2014 Q3 Form 10-Q Financial Statement

#000139047814000043 Filed on August 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2014 Q3 Form 10-Q Financial Statement

#000139047814000043 Filed on August 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls